• Sanofi halted clinical development of amlitelimab for moderate-to-severe atopic dermatitis.
• Plans to skip global regulatory filings following a strategic review of its development portfolio.
• Decision reflects an unfavorable overall efficacy-safety assessment to date.
• Long-term Phase 3 ESTUARY extension showed durable response, but the drug was not seen as a meaningful advance over standard care.
• 2026 financial guidance unchanged; Phase 2 celiac disease study continues with results expected in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240130OMX_____CNEWS_FR_GNW1001214208_fr) on July 24, 2026, and is solely responsible for the information contained therein.